28 Results

People

  1. Batlevi
    Batlevi
  2. Zelenetz
    Zelenetz
  3. Matasar
    Matasar
  4. Noy
    Noy
  5. Palomba
    Palomba
  6. Horwitz
    Horwitz
  7. Hamlin
    Hamlin
  8. Kumar
    Kumar
  9. Moskowitz
    Moskowitz
  10. Hamilton
    Hamilton

Groups

  1. Center for Hematologic Malignancies (28)
  2. Department of Medicine (28)
  3. GSK Faculty (28)
  4. Hematologic Malignancies, Division of (28)
  5. Lymphoma (28)
  6. Human Oncology and Pathogenesis Program (27)
  7. Survivorship Research (25)
  8. Epidemiology and Biostatistics (21)
  9. Population Sciences Research Program (20)
  10. Executive Committee, Center for Hematologic Malignancies (19)
  1. "Center for Hematologic Malignancies"
  2. "Department of Medicine"
  3. "GSK Faculty"
  4. "Andrew Zelenetz"
  5. "Connie Batlevi"
Formats
  1. Meeting Abstract (23)
  2. Journal Article (4)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (28)
  2. Department of Medicine (28)
  3. GSK Faculty (28)
  4. Hematologic Malignancies, Division of (28)
  5. Lymphoma (28)
  6. Human Oncology and Pathogenesis Program (27)

More Groups

People
  1. Andrew Zelenetz (28)
  2. Connie Batlevi (28)
  3. Matthew Matasar (24)
  4. Ariela Noy (22)
  5. Maria Palomba (22)
  6. Steven Horwitz (20)

More People

Years
  1. 2023 (2)
  2. 2022 (4)
  3. 2021 (4)
  4. 2020 (4)
  5. 2019 (2)
  6. 2018 (1)

More Years

Publications
  1. Blood (20)
  2. Blood Advances (2)
  3. Journal of Clinical Oncology (2)
  4. Blood Cancer Journal (1)
  5. Cancer Cell (1)
  6. Hematological Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (22)
  2. American Society of Clinical Oncology (2)
  3. Cell Press (1)
  4. Elsevier Science, Inc. (1)
  5. Nature Publishing Group (1)
  6. Wiley Blackwell (1)

Results (28)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
    Journal Article

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
    Research Letter

    Stuver, R.; Shah, G. L.; Korde, N. S.; Roeker, L. E.; Mato, A. R.; Batlevi, C. L.; Chung, D. J.; Doddi, S.; Falchi, L.; Gyurkocza, B.; more...
    Cancer Cell (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save